atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place in Boston, MA from August 13-15, 2024.
Key details of atai's involvement include:
- A fireside chat scheduled for Wednesday, August 14 at 11:00 A.M. EDT
- One-on-one investor meetings
- A webcast link provided for remote access
An archived replay of the fireside chat will be available on the Investors section of atai's website under Events for up to 90 days following the conference.
atai Life Sciences (NASDAQ: ATAI), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per i disturbi della salute mentale, ha annunciato la propria partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento si svolgerà a Boston, MA dal 13 al 15 agosto 2024.
I dettagli chiave del coinvolgimento di atai includono:
- Una chiacchierata informale programmata per mercoledì 14 agosto alle 11:00 A.M. EDT
- Incontri individuali con gli investitori
- Un link per la diretta streaming fornito per l'accesso remoto
Una registrazione archiviata della chiacchierata informale sarà disponibile nella sezione Investitori del sito web di atai sotto Eventi per un massimo di 90 giorni dopo la conferenza.
atai Life Sciences (NASDAQ: ATAI), una empresa biofarmacéutica en etapa clínica enfocada en tratamientos para trastornos de salud mental, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento se llevará a cabo en Boston, MA del 13 al 15 de agosto de 2024.
Los detalles clave de la participación de atai incluyen:
- Una charla junto a la chimenea programada para miércoles 14 de agosto a las 11:00 A.M. EDT
- Reuniones individuales con inversores
- Un enlace de transmisión en vivo proporcionado para acceso remoto
Una repetición archivada de la charla junto a la chimenea estará disponible en la sección de Inversores del sitio web de atai en Eventos durante un máximo de 90 días después de la conferencia.
atai 생명과학 (NASDAQ: ATAI)는 정신 건강 장애 치료에 집중하는 임상 단계의 생물 제약 회사로, Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 본 행사는 2024년 8월 13일부터 15일까지 보스턴, MA에서 개최됩니다.
atai의 참여 주요 사항은 다음과 같습니다:
- 8월 14일 수요일 오전 11:00 EDT에 예정된 파이어사이드 채팅
- 개별 투자자 회의
- 원격 접근을 위한 웹캐스트 링크 제공
파이어사이드 채팅의 아카이브 재생은 컨퍼런스 후 최대 90일 동안 atai 웹사이트의 투자자 섹션 이벤트에서 제공될 것입니다.
atai Life Sciences (NASDAQ: ATAI), une entreprise biopharmaceutique en phase clinique axée sur les traitements des troubles de la santé mentale, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'événement se tiendra à Boston, MA du 13 au 15 août 2024.
Les détails clés de l'implication d'atai incluent:
- Une discussion informelle prévue pour mercredi 14 août à 11h00 EDT
- Des réunions individuelles avec des investisseurs
- Un lien de webdiffusion fourni pour un accès à distance
Un enregistrement archivé de la discussion informelle sera disponible dans la section Investisseurs du site web d'atai sous Événements pendant 90 jours suivant la conférence.
atai Life Sciences (NASDAQ: ATAI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen für psychische Gesundheitsstörungen konzentriert, hat seine Teilnahme an der 44. Jahreskonferenz für Wachstumsunternehmen von Canaccord Genuity angekündigt. Die Veranstaltung findet von 13. bis 15. August 2024 in Boston, MA statt.
Wichtige Details zur Beteiligung von atai sind:
- Ein Kamin-Gespräch, das für Mittwoch, den 14. August um 11:00 Uhr EDT geplant ist
- Einzelgespräche mit Investoren
- Ein Live-Stream-Link, der für den Remote-Zugang bereitgestellt wird
Eine archivierte Wiederholung des Kamin-Gesprächs wird bis zu 90 Tage nach der Konferenz im Bereich Investoren auf der Website von atai unter Veranstaltungen verfügbar sein.
- None.
- None.
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation:
Format: Fireside chat and 1x1 investor meetings
Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. EDT
Webcast link: Here
An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
Contact Information
Investor Contact:
Media Contact:
FAQ
When is atai Life Sciences (ATAI) participating in the Canaccord Genuity Growth Conference?
What type of events will atai Life Sciences (ATAI) be involved in at the Canaccord conference?
How can investors access atai Life Sciences' (ATAI) presentation at the Canaccord conference?
Where is the Canaccord Genuity 44th Annual Growth Conference being held?
